Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4099-4103

  Kawamura, Ikuo ^a   Yamamoto, Nobuchika ^a   Sakai, Fumihiko ^a   Yamazaki, Harumi ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

B16 melanoma; Bezafibrate; Cachexia; Lipoprotein lipase activator; NO 1886

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; BEZAFIBRATE; FATTY ACID; GLUCOSE; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CACHEXIA; CONTROLLED STUDY; DRUG EFFECT; EPIDIDYMIS FAT; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; MALE; MELANOMA B16; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; BENZAMIDES; BEZAFIBRATE; CACHEXIA; CHOLESTEROL; ENZYME ACTIVATORS; EPIDIDYMIS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; LIPID METABOLISM; LIPOPROTEIN LIPASE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ORGANOPHOSPHORUS COMPOUNDS; TRIGLYCERIDES;

EID: 0032763985     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. DeWys WD, Begg C, Lavin PT, B and PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenhaum C, Silverstein MN, Skeel RT, Sponzo RW and Tormey DC: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491-497, 1980.
2. Kern KA and Norton JA: Cancer cachexia. J Parenteral Enteral Nutr 12: 286-298, 1988.
3. Curtis EB, Krech R and Walsh TD: Common symptoms in patients with advanced cancer. J Palliat Care 7: 25-29, 1991.
4. Legaspi A, Jeevanandam M, Starnes HF Jr. and Brennan MF: Whole body lipid and energy metabolism in the cancer patient. Metabolism 36: 958-963, 1987.
5. Mulligan HD, Beck SA and Tisdale MJ: Lipid metabolism in cancer cachexia. Br J Cancer 66: 57-61, 1992.
6. Lanza-Jacoby S, Miller EE and Rosato FE: Changes in the activities of lipoprotein lipase and lipogenic enzymes in tumor-bearing rats. Lipids 17: 944-949, 1982.
7. Vlassara H, Spiegel RJ, Doval DS and Cerami A: Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm Metabol Res 18: 698-703, 1986.
8. Evans RD and Williamson DH: Tissue-specific effects of rapid tumor growth on lipid metabolism in the rat during lactation and on litter removal. Biochem J 252: 65-72, 1988.
9. Noguchi Y, Vydelingum NA, Younes RN, Fried SK and Brennan MF: Tumor-induced alterations in tissue lipoprotein lipase activity and mRNA levels. Cancer Res 51: 863-869, 1991.
10. Cryer A: Tissue lipoprotein lipase activity and its action in lipoprotein metabolism. Int J Biochem 13: 525-541, 1981.
11. Eckel RH: Lipoprotein lipase: a multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320: 1060-1068, 1989.
12. Kawamura I, Yamamoto N, Sakai F, Yamazaki H, Naoe Y, Inami M, Manda T and Shimomura K: Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Anticancer Res 19: 341-348, 1999.
13. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T and Taguchi T: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50: 2290-2295, 1990.
14. Dilman VM, Berstein LM, Ostroumova MN, Tsyrlina YV and Golubev AG: Peculiarities of hyperlipidaemia in tumor patients. Br J Cancer 43: 637-643, 1981.
15. Vessby B, Lithell H and Ledermann H: Elavated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate. Atherosclerosis 44: 113-118, 1982.
16. Kobayashi J, Takahashi K, Tashiro J, Shirai K, Saito Y, Yoshida S, Hashimoto H, Fukamachi I, Niihara K and Sasaki N: Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia. Arzneim Forsch Drug Res 44: 145-148, 1994.
17. Hagi A, Hirai I, Kohri H and Tsutsumi K: The novel compound NO-1886 activates lipoprotein lipase in primary cultured adipose and skeletal muscle cells. Biol Pharm Bull 20: 1108-1110, 1997.
18. Chiba T, Miura S, Sawamura F, Uetsuka R, Tomita I, Inoue Y, Tsutsumi K and Tomita T: Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Arterioscler Thromb Vasc Biol 17: 2601-2608, 1997.
19. Hara T, Kusunoki M, Tsutsumi K, Okada K, Sakamoto S, Ohnaka M, Nakamura T, Miyata T, Nakayama K, Fukatsu A, Kato K, Kakumu S and Nakaya Y: A lipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxation of rat aorta associated with aging. Eur J Pharmacol 350: 75-79, 1998.
20. Nomura K, Noguchi Y and Matsumoto A: Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate. Jpn J Surg 26: 89-94, 1996.
21. Ohara M, Tsutsumi K and Ohsawa N: Suppression of carcass weight loss in cachexia in rats bearing leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator. Metabolism 47: 101-105, 1998.